Saher Taj Shiza
University of Connecticut & Hartford Hospital, USAPresentation Title:
Cholesterol management in cardiovascular disease prevention and treatment
Abstract
Cholesterol management is a crucial aspect
of preventing cardiovascular disease (cvd), a leading cause of morbidity and
mortality worldwide. Elevated levels of low-density lipoprotein cholesterol
(ldl-c) are a major risk factor for atherosclerotic cardiovascular disease
(ascvd). Effective management of cholesterol levels can significantly reduce
the risk of cardiovascular events.
Treatment strategies
Several treatment strategies are available
for cholesterol management, including:
1. *statins*: hmg-coa reductase inhibitors
that reduce ldl-c production in the liver. Statins are the primary treatment
for hypercholesterolemia and have been shown to reduce cardiovascular events.
2. *ezetimibe*: a cholesterol absorption
inhibitor that reduces ldl-c levels by inhibiting intestinal cholesterol
absorption. Often used in combination with statins.
3. *bempedoic acid*: an atp citrate lyase
inhibitor that reduces ldl-c production in the liver. Used for patients who
cannot tolerate statins or require additional ldl-c reduction.
4. *pcsk9 inhibitors (pcsk9i)*: monoclonal
antibodies that target pcsk9, a protein that degrades ldl receptors in the
liver. Pcsk9i increase ldl receptor density, reducing ldl-c levels.
5. *inclisiran*: a small interfering rna
(sirna) that targets pcsk9 mrna, reducing pcsk9 protein production and
increasing ldl receptor density.
Stepwise approach
A stepwise approach to cholesterol
management is recommended, with treatment intensity and medication selection
based on individual patient risk and ldl-c levels. This approach includes:
1. Lifestyle modifications (diet, exercise,
weight loss)
2. Statin therapy
3. Addition of ezetimibe or bempedoic acid
for further ldl-c reduction
4. Pcsk9i or inclisiran for high-risk
patients or those with refractory hypercholesterolemia
Good outcomes
With a stepwise approach and the use of
newer drugs, good outcomes can be achieved in cholesterol management. These
include:
1. Significant reductions in ldl-c levels
2. Reduced risk of cardiovascular events
(myocardial infarction, stroke, cardiovascular death)
3. Improved patient outcomes and quality of
life
|
By adopting a comprehensive and
individualized approach to cholesterol management, healthcare providers can
reduce the burden of cardiovascular disease and improve patient outcomes.
|
Biography
Saher Shiza is a
globally experienced cardiology specialist with a strong background in clinical
cardiology and preventive medicine. A graduate of Deccan College of Medical
Sciences, she worked as a cardiology specialist in India and Saudi Arabia for 8
years before pursuing advanced training in the US.
Saher Shiza holds a
Postgraduate Program in Clinical Cardiology from Johns Hopkins University
School of Medicine and a Fellowship in Preventive Cardiology from the Indian
Medical Association. Currently, they are a Preventive Cardiology Fellow at the
University of Connecticut, following a stint in Internal Medicine Residency in
New York.
A recipient of the
prestigious Trudy Bush Award for research in women's cardiovascular health, she
is dedicated to studying cardiovascular disease behavior in vulnerable
populations. Her passion lies in advancing preventive strategies and reducing
cardiovascular risk. With a strong commitment to cardiovascular health,
Dr.Saher Shiza aims to make impactful contributions to the field through
research, education, and clinical practice. Their work is driven by a vision of
achieving global cardiovascular safety and promoting health equity.
Organization Location
1309 Coffeen Avenue, STE 1200, Sheridan, Wyoming 82801, USA
Mail us at
Drop us an email for Program enquiry
primaryhealthcare@scientexconferences.com
General Queries
contact@scientexconferences.com
Sponsors / Exhibiting / Advertising
finance@scientexconferences.com
primaryhealthcare@scientexconferences.com
Our Social Presence
Call us at
USA :(+1) 307 463 7832